CA
NZ
UK
AU
IND
US
…
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Coloplast A is a Denmark-based medical device company focused on ostomy, continence, wound and skin care products sold via specialist channels and healthcare providers; long-term growth may be supported by aging populations, rising chronic disease prevalence, recurring consumable revenue and expansion in emerging markets. Investors may find it attractive because focused market positions and a consumable-driven revenue mix could enable relatively predictable cash flows.
Key risks include currency and reimbursement/regulatory exposure, competition from larger medtech companies, and operational disruptions such as supply-chain or manufacturing issues.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Income before tax | 5799.00M | 6395.00M | 6025.00M | 6127.00M | 6233.00M |
| Net income | 3425.00M | 5052.00M | 4783.00M | 4706.00M | 4825.00M |
| Selling general administrative | - | 1244.00M | 1115.00M | 1005.00M | 762.00M |
| Selling and marketing expenses | - | 8825.00M | 7518.00M | 6797.00M | 5485.00M |
| Gross profit | 17082.00M | 18269.00M | 16328.00M | 15529.00M | 13313.00M |
| Reconciled depreciation | - | 1290.00M | 1069.00M | 930.00M | 792.00M |
| Ebit | 6577.00M | 7190.00M | 6661.00M | 6439.00M | 6355.00M |
| Ebitda | 7852.00M | 8480.00M | 7730.00M | 7864.00M | 7233.00M |
| Depreciation and amortization | 1275.00M | 1290.00M | 1069.00M | 1425.00M | 878.00M |
| Operating income | 7139.00M | 7320.00M | 6771.00M | 6439.00M | 6355.00M |
| Other operating expenses | 19116.00M | 19710.00M | 17655.00M | 15669.00M | 13071.00M |
| Interest expense | 777.06M | 882.00M | 638.00M | 172.00M | 25.00M |
| Tax provision | - | 1343.00M | 1242.00M | 1421.00M | 1408.00M |
| Interest income | - | 155.00M | 111.00M | 12.00M | 11.00M |
| Net interest income | - | -725.00M | -604.00M | -224.00M | -45.00M |
| Income tax expense | 2375.00M | 1343.00M | 1242.00M | 1421.00M | 1408.00M |
| Total revenue | 26254.00M | 27030.00M | 24500.00M | 22579.00M | 19426.00M |
| Total operating expenses | 9944.00M | 10949.00M | 9483.00M | 8619.00M | 6958.00M |
| Cost of revenue | 9172.00M | 8761.00M | 8172.00M | 7050.00M | 6113.00M |
| Total other income expense net | -1339.00M | -925.00M | -746.00M | -312.00M | -122.00M |
| Net income from continuing ops | - | 5052.00M | 4783.00M | 4706.00M | 4825.00M |
| Net income applicable to common shares | - | - | - | 4706.00M | 4825.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Total assets | 48463.00M | 48073.00M | 48159.00M | 34956.00M | 15841.00M |
| Intangible assets | 10503.00M | 10957.00M | 11281.00M | 8469.00M | 1623.00M |
| Other current assets | 412.12M | 5984.00M | - | - | 3892.00M |
| Total liab | 32309.00M | 30131.00M | 30860.00M | 26664.00M | 7673.00M |
| Total stockholder equity | 16154.00M | 17942.00M | 17299.00M | 8292.00M | 8168.00M |
| Other current liab | 2596.00M | 2481.00M | 1.00M | 4241.00M | 8.00M |
| Common stock | 228.45M | 228.00M | 228.00M | 216.00M | 216.00M |
| Capital stock | - | - | 228.00M | 216.00M | 216.00M |
| Retained earnings | 17710.00M | 15391.00M | 14632.00M | 5386.00M | 5406.00M |
| Other liab | - | - | - | 2473.00M | 910.00M |
| Good will | 19367.00M | 19375.00M | 19974.00M | 11808.00M | 2028.00M |
| Other assets | - | - | - | 1891.00M | 1655.00M |
| Cash | 948.88M | 788.00M | 911.00M | 414.00M | 448.00M |
| Total current liabilities | 6518.00M | 10204.00M | 16311.00M | 7336.00M | 6314.00M |
| Current deferred revenue | - | - | 7671.00M | - | 2933.00M |
| Net debt | 21735.12M | 21841.00M | 18656.00M | 18294.00M | 2338.00M |
| Short term debt | 2595.00M | 5338.00M | 7345.00M | 1853.00M | 2337.00M |
| Short long term debt | - | - | 7115.00M | 1644.00M | 2160.00M |
| Short long term debt total | 22684.00M | 22629.00M | 19567.00M | 18708.00M | 2786.00M |
| Other stockholder equity | - | 2323.00M | 2439.00M | 2690.00M | 2546.00M |
| Property plant equipment | - | - | - | 4133.00M | 3584.00M |
| Total current assets | 10474.00M | 10444.00M | 9937.00M | 8772.00M | 6994.00M |
| Net tangible assets | - | - | - | -11817.00M | 4601.00M |
| Short term investments | - | - | - | 219.00M | 226.00M |
| Net receivables | 5186.00M | - | 4315.00M | 4659.00M | 3720.00M |
| Long term debt | - | - | 11558.00M | 16359.00M | - |
| Inventory | 3927.00M | 3672.00M | 3522.00M | 3187.00M | 2428.00M |
| Accounts payable | 1327.00M | 1519.00M | 1294.00M | 1242.00M | 1036.00M |
| Accumulated other comprehensive income | -1785.00M | - | - | - | - |
| Non currrent assets other | 316.61M | 102.00M | 104.00M | 250.00M | 252.00M |
| Non current assets total | 37989.00M | 37629.00M | 38222.00M | 26184.00M | 8847.00M |
| Capital lease obligations | - | - | 894.00M | 705.00M | 626.00M |
| Breakdown | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
| Investments | - | -1336.00M | -8957.00M | -2.00M | 16.00M |
| Change to liabilities | - | - | - | 337.00M | 224.00M |
| Total cashflows from investing activities | -1178.00M | -1336.00M | - | -11759.00M | -2011.00M |
| Net borrowings | - | 2970.00M | - | 10730.00M | 848.00M |
| Total cash from financing activities | -4886.00M | -1518.00M | 5265.00M | 6591.00M | -3176.00M |
| Change to operating activities | - | - | - | -295.00M | 97.00M |
| Net income | 3425.00M | 5052.00M | 6771.00M | 6439.00M | 6155.00M |
| Change in cash | 197.93M | -123.00M | 497.00M | -34.00M | 125.00M |
| Begin period cash flow | 750.95M | 911.00M | 414.00M | 448.00M | 323.00M |
| End period cash flow | 948.88M | 788.00M | 911.00M | 414.00M | 448.00M |
| Total cash from operating activities | 6259.00M | 2766.00M | 4226.00M | 5099.00M | 5290.00M |
| Issuance of capital stock | - | 500.00M | 9134.00M | - | 306.00M |
| Depreciation | 1275.00M | 1290.00M | 1069.00M | 930.00M | 792.00M |
| Other cashflows from investing activities | 0.45M | -165.00M | - | - | - |
| Dividends paid | 4670.00M | 4720.00M | 4247.00M | 4041.00M | 3830.00M |
| Change to inventory | -415.00M | -290.00M | -474.00M | -540.00M | -161.00M |
| Change to account receivables | -34.00M | -506.00M | - | -351.00M | -235.00M |
| Sale purchase of stock | - | - | 0.00M | -619.00M | -500.00M |
| Other cashflows from financing activities | -264.98M | -268.00M | 378.00M | 16649.00M | 848.00M |
| Change to netincome | - | - | - | 312.00M | -252.00M |
| Capital expenditures | 1230.00M | 1166.00M | 1241.00M | 1135.00M | 1966.00M |
| Change in working capital | -739.00M | -1032.00M | -893.00M | -849.00M | -75.00M |
| Other non cash items | 2298.00M | -2544.00M | -2721.00M | -1421.00M | -1582.00M |
| Free cash flow | 5029.00M | 1600.00M | 2985.00M | 3964.00M | 3324.00M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLPBY Coloplast A |
-0.01 0.14% |
7.16 | 34.26 | 15.60 | 0.52 | 7.09 | 4.13 | 12.88 |
| ISRG Intuitive Surgical Inc |
-1.70 0.38% |
444.18 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
-3.50 1.72% |
200.50 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
-2.13 2.10% |
99.11 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.13 0.07% |
195.16 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Dressings and Biologics segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; Peristeen Plus, a transanal irrigation system; and Peristeen Light, a low-volume transanal irrigation. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as erectile dysfunction, urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
| Name | Title | Year Born |
|---|---|---|
| Mr. Kristian Villumsen | Pres & CEO | 1970 |
| Mr. Anders Lonning-Skovgaard | Exec. VP & CFO | 1972 |
| Mr. Allan Rasmussen | Exec. VP of Global Operations | 1967 |
| Mr. Nicolai Buhl Andersen | Exec. VP of Innovation | 1969 |
| Mr. Paul Marcun | Exec. VP of Growth | 1967 |
| Mr. Thomas Barfod | Sr. Controller & Employees Representative Director | 1970 |
| Ellen Bjurgert | VP of Investor Relations | NA |
| Dennis Kaysen | Director of Corp. Communications | NA |
| Dorthe Ronnau | Sr. VP of People & Culture | 1966 |
| Mr. Alain Morvan | Sr. VP of Sales Europe | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...